StockData
Bluejay Diagnostics, Inc. logo

Bluejay Diagnostics, Inc. (BJDX) company profile

BJDXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$2.15−0.14 (-5.90%)

Close on Nov 17, 2026Market cap $9.63MP/E –Yield –

About Bluejay Diagnostics

Surgical & Medical Instruments & Apparatus, SIC 3841

Bluejay Diagnostics, Inc. is a medical diagnostics company dedicated to improving patient care in critical healthcare environments, particularly for individuals diagnosed with sepsis. The company is actively developing point-of-care, rapid diagnostic tests that use whole blood samples with its proprietary Symphony technology platform. This platform comprises a specialized centrifugal analyzer and single-use protein detection cartridges designed to measure key biomarkers, with its lead product candidate focused on interleukin-6 testing. Bluejay Diagnostics intends to serve healthcare providers operating in critical care environments, with a particular focus on intensive care units and emergency rooms within acute care facilities.

The company focuses its commercialization plans on large critical care hospital facilities situated across the United States. Its technology relies on cartridge manufacturing and development operations conducted through a partner facility located in Japan. Bluejay Diagnostics maintains its corporate headquarters in Acton, Massachusetts.

Summary of the business section of Bluejay Diagnostics's latest annual report, written by StockData.

Company profile

Company

Legal name
Bluejay Diagnostics, Inc.
Founded
2015
Headquarters
Acton, MA
Address
360 Massachusetts Avenue, Suite 203 01720
Phone
(978) 631-0152
Employees
6, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Wolf & Company, P.C., Boston, Massachusetts

Stock & identifiers

Ticker
BJDX
Exchange
Nasdaq
IPO date
Nov 12, 2021
Shares outstanding
4M, Aug 7, 2026
Public float
$2.57M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-4 reverse, Jan 29, 2026; 1-for-50 reverse, Mar 31, 2025; 1-for-50 reverse, Nov 18, 2024; 1-for-8 reverse, Jun 20, 2024; 1-for-20 reverse, Jul 24, 2023
SEC CIK
1704287
CUSIP
095633608
ISIN
US0956336087
FIGI
BBG012TKJCJ1
Share class FIGI
BBG012TKJDC6
EIN
47-3552922

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Indranil DeyPresident and CEO, Director40,649
Svetlana DeyDirector12,628
Douglas Clark WurthDirector1,121,491
Fred S. ZeidmanDirector12,500
Donald R. ChaseDirector12,525

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryIncentive payOtherTotalvs. prior year
Neil Dey
President & Chief Executive Officer
$328.19K$137.50K$7.86K$473.56K+63%
Jason Cook
Chief Technology Officer
$111.60K–$214.64K$326.24K+30%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 12, 2021
Offer price
$10.00
Securities offered
2,160,000
Gross proceeds
$21.60M
Exchange
Nasdaq
First trading day
Nov 10, 2021
First-day close
$5.32-46.8%
Lock-up ends (est.)
May 9, 2022

“Per Unit (2) Total (3) Public offering price $ 10.00 $ 21,600,000 Underwriting discounts (1) $ 0.80 $ 1,728,000 Proceeds to us, before expenses $ 9.20 $ 19,872,000 ____________ (1) The underwriters will receive compensation in addition to the underwriting discounts and commissions.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 2, 2026, we have 6 full-time employees, which includes one executive officer.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?